Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word

NCT03054818 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT03054818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03054818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2016
Completion date
June 30, 2018
Enrollment
4,000 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration (wamd)